As survinin expression has been linked to drug resistance in leukemia, combinatorial treatment with YM155 and Trametinib could potentially have a beneficial effect on decreasing the chances for relapse, due to the inhibition of survivin and putative compensatory expression induced by the MAPK pathway. The gene discussed is BIRC5; the disease is leukemia.